Lasa Supergenerics Limited
Lasa Supergenerics Limited (LASA) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
lasalabs.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 | Jun 2025 | Sept 2025 |
|---|---|---|---|
| Sales | 39 Cr | 20 Cr | 3 Cr |
| Operating expenses (approx.) | 36 Cr | 21 Cr | 7 Cr |
| EBITDA | 3 Cr | -0.50 Cr | -4 Cr |
| OPM % | 8.7% | -2.5% | -130.6% |
| Other income | 2 Cr | 0.13 Cr | 0.0070 Cr |
| Interest | 0.11 Cr | 0.03 Cr | 0.12 Cr |
| Depreciation | 4 Cr | 2 Cr | 2 Cr |
| Profit before tax | -22 Cr | -23 Cr | -6 Cr |
| Tax % | 35.4% | 6.3% | -10.1% |
| Net profit | -14 Cr | -21 Cr | -6 Cr |
| EPS (₹) | ₹-2.85 | ₹-4.22 | ₹-1.25 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2025 | TTM |
|---|---|---|
| Sales | 142 Cr | Sign in for TTM |
| Operating expenses (approx.) | 136 Cr | Sign in for TTM |
| EBITDA | 6 Cr | Sign in for TTM |
| OPM % | 4.4% | Sign in for TTM |
| Other income | 5 Cr | Sign in for TTM |
| Interest | 3 Cr | Sign in for TTM |
| Depreciation | 12 Cr | Sign in for TTM |
| Profit before tax | -19 Cr | Sign in for TTM |
| Tax % | 23.9% | Sign in for TTM |
| Net profit | -15 Cr | Sign in for TTM |
| EPS (₹) | ₹-2.95 | Sign in for TTM |
| Dividend payout % | — | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2025 |
|---|---|
| Equity capital | 50 Cr |
| Reserves | 34 Cr |
| Borrowings | 3 Cr |
| Other liabilities | 15 Cr |
| Total liabilities | 102 Cr |
| Fixed assets (net) | 48 Cr |
| CWIP | 0.25 Cr |
| Investments | 0 Cr |
| Loans & advances | 0.05 Cr |
| Inventories | 24 Cr |
| Trade receivables | 1 Cr |
| Cash & bank | 0.28 Cr |
| Other assets | 27 Cr |
| Total assets | 102 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2025 |
|---|---|
| Cash from operating activity | -3 Cr |
| Cash from investing | 8 Cr |
| Cash from financing | -6 Cr |
| Net cash flow | -0.33 Cr |
| Free cash flow (OCF − Capex) | -3 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2025 |
|---|---|
| ROCE % | -19.3% |
| ROE % | -17.6% |
| Debtor days | 4 |
| Inventory days | 82 |
| Days payable | 34 |
| Cash conversion cycle | 52 |
| Debt / equity | 0.03 |
| Current ratio | 1.90 |
| Net debt / EBITDA | 0.37 |
Compare with peers
Loading peers…